Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45

RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S.

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential